Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats

Chest. 2005 Sep;128(3):1812-21. doi: 10.1378/chest.128.3.1812.

Abstract

Objectives: The normal expression of Ca2+-handling protein is critical for efficient myocardial function. The present study was designed to test the hypothesis that beta-blocker treatment may attenuate left ventricular (LV) remodeling and cardiac contractile dysfunction in the failing heart, which may be associated with alterations of Ca2+-handling protein

Methods: We investigated the change of LV remodeling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 mg/kg/d) or metoprolol (60 mg/kg/d) treatment for 6 weeks (n = 9 in the MI plus carvedilol group, and n = 8 in every other group). The expression of messenger RNA and proteins of sarcoplasmic reticulum Ca2+-adenosine triphosphatase (SERCA) and phospholamban in cardiomyocytes of all rats were also measured

Results: There was significant LV remodeling and cardiac contractile dysfunction in MI rats. The messenger RNA and protein expression of SERCA were down-regulated (p < 0.01), but the expression of phospholamban messenger RNA and protein were up-regulated (p < 0.01) in MI rats compared to sham-operated rats. After the treatment with beta-blockers, LV remodeling and function were clearly improved. Carvedilol was better in attenuating the weight of the LV and the relative weight of the right ventricle than metoprolol (p < 0.05). beta-Blockers restored the low expression of SERCA (p < 0.05) but showed no effect on phospholamban expression (p > 0.05). Moreover, carvedilol induced a more significant improvement of SERCA expression than metoprolol (p < 0.05)

Conclusions: Beta-blockers are effective in preventing LV remodeling and cardiac contractile dysfunction in the failing heart. The molecular mechanism may be related to normalization of SERCA expression.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / pharmacology*
  • Animals
  • Calcium-Binding Proteins / analysis
  • Calcium-Binding Proteins / biosynthesis
  • Calcium-Transporting ATPases / analysis
  • Calcium-Transporting ATPases / biosynthesis
  • Carbazoles / pharmacology
  • Carrier Proteins / analysis
  • Carrier Proteins / biosynthesis*
  • Carvedilol
  • Heart Failure / etiology
  • Heart Failure / physiopathology*
  • Heart Ventricles / chemistry
  • Heart Ventricles / drug effects
  • Male
  • Metoprolol / pharmacology
  • Models, Animal
  • Myocardial Contraction / drug effects
  • Myocardial Infarction / complications
  • Myocardial Infarction / physiopathology*
  • Myocytes, Cardiac / chemistry
  • Myocytes, Cardiac / drug effects
  • Propanolamines / pharmacology
  • RNA, Messenger
  • Rats
  • Rats, Sprague-Dawley
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases
  • Ventricular Dysfunction, Left / etiology
  • Ventricular Dysfunction, Left / prevention & control
  • Ventricular Function, Left / drug effects*
  • Ventricular Remodeling / drug effects

Substances

  • Adrenergic beta-Antagonists
  • Calcium-Binding Proteins
  • Carbazoles
  • Carrier Proteins
  • Propanolamines
  • RNA, Messenger
  • phospholamban
  • Carvedilol
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases
  • Calcium-Transporting ATPases
  • Metoprolol